Premium
Anti‐tumor effect of internal image bearing anti‐idiotypic monoclonal antibody in relation to GM 3 ganglioside
Author(s) -
Jinnohara Tsuneharu,
Tsujisaki Masayuki,
Sasaki Shigeru,
Hinoda Yuji,
Taniguchi Masaru,
Imai Kohzoh
Publication year - 1998
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19980504)76:3<345::aid-ijc11>3.0.co;2-a
Subject(s) - monoclonal antibody , immunogenicity , ganglioside , antigen , immunotherapy , antibody , idiotype , immune system , melanoma , cd8 , biology , immunology , cancer research , biochemistry
Anti‐idiotypic antibodies are a new type of useful tools for the possible treatment of cancer patients, since some act as antigen specific immunomodulators. Anti‐idiotypic monoclonal antibody (anti‐Id MAb) D704 (Ab2) was established which bore the internal image of the determinant defined by MAb M2590 (Ab1) against a sialic acid residue on GM 3 ganglioside. In an in vivo syngeneic tumor system, anti‐Id MAb D704 was more effective in preventing tumor progression, as compared with anti‐GM 3 MAb or no treatment. Significant suppression of tumor growth and prolongation of survival by administration of anti‐Id MAb D704 in an animal group inoculated with 1 × 10 4 /mouse melanoma cells were seen, but not in a group inoculated with 5 × 10 4 cells/mouse. In an active specific immunotherapy protocol utilizing Ab2, the activity of anti‐anti‐Id antibodies (Ab3) specific for GM 3 (antigen) which has a weak immunogenicity only, was maintained for more than 3 months. Ab2 generated cellular anti‐tumor immune responses, including delayed type hypersensitivity (DTH) reaction. Immunohistological analysis indicated a marked infiltration of CD4 and CD8 positive cells into the DTH sites. Our results suggest that internal image bearing anti‐Id MAbs have a therapeutic potential against tumors if the number of melanoma cells is relatively low or if hosts are at an early stage of melanoma progression. Int. J. Cancer 76:345–353, 1998. © 1998 Wiley‐Liss, Inc.